Skip to main content

ADVERTISEMENT

Chronic Lymphocytic Leukemia

Acalabrutinib Demonstrates Favorable Safety and Efficacy in Relapsed/Refractory CLL
Videos
06/17/2020
Paolo Ghia, MD, PhD, discusses the results from the ASCEND study, which compared acalabrutinib monotherapy to physician’s choice of therapy in patients with relapsed or refractory CLL.
Paolo Ghia, MD, PhD, discusses the results from the ASCEND study, which compared acalabrutinib monotherapy to physician’s choice of therapy in patients with relapsed or refractory CLL.
Paolo Ghia, MD, PhD, discusses...
06/17/2020
Oncology
News
12/09/2019
According to updated data presented at ASH 2019, the next-generation BTK inhibitor zanubrutinib yields a high overall and durable response rate in patients with CLL/SLL.
According to updated data presented at ASH 2019, the next-generation BTK inhibitor zanubrutinib yields a high overall and durable response rate in patients with CLL/SLL.
According to updated data...
12/09/2019
Oncology
Videos
11/13/2019
Jennifer Woyach, MD, discusses treatment options for older patients with CLL and why treating older patients differs from treating younger patients.
Jennifer Woyach, MD, discusses treatment options for older patients with CLL and why treating older patients differs from treating younger patients.
Jennifer Woyach, MD, discusses...
11/13/2019
Oncology
Videos
11/12/2019
Matthew S. Davids, MD, MMSc, discusses venetoclax resistance in CLL and how to manage patients resistant to the drug.
Matthew S. Davids, MD, MMSc, discusses venetoclax resistance in CLL and how to manage patients resistant to the drug.
Matthew S. Davids, MD, MMSc,...
11/12/2019
Oncology
Videos
11/12/2019
Richard Furman, MD, explains how best to control CLL patients who progress on BTK inhibitor therapy.
Richard Furman, MD, explains how best to control CLL patients who progress on BTK inhibitor therapy.
Richard Furman, MD, explains how...
11/12/2019
Oncology
Podcasts
09/14/2019
Paul Barr, MD, shares 6-year follow-up data from patients with CLL or SLL treated with ibrutinib on the RESONATE study.
Paul Barr, MD, shares 6-year follow-up data from patients with CLL or SLL treated with ibrutinib on the RESONATE study.
Paul Barr, MD, shares 6-year...
09/14/2019
Oncology
Videos
06/18/2019
Jacqueline C. Barrientos, MD, MS, explains why combining therapies is beneficial for the treatment of patients with CLL.
Jacqueline C. Barrientos, MD, MS, explains why combining therapies is beneficial for the treatment of patients with CLL.
Jacqueline C. Barrientos, MD,...
06/18/2019
Oncology
Videos
04/06/2019
Jacqueline C. Barrientos, MD, MS, explains the importance of sequencing monotherapy in chronic lymphocytic leukemia.
Jacqueline C. Barrientos, MD, MS, explains the importance of sequencing monotherapy in chronic lymphocytic leukemia.
Jacqueline C. Barrientos, MD,...
04/06/2019
Oncology
Videos
04/06/2019
Richard R. Furman, MD, discusses ibrutinib compared with the standard chemoimmunotherapeutic regimen of intravenous fludarabine, cyclophosphamide, and rituximab, for patients with CLL.
Richard R. Furman, MD, discusses ibrutinib compared with the standard chemoimmunotherapeutic regimen of intravenous fludarabine, cyclophosphamide, and rituximab, for patients with CLL.
Richard R. Furman, MD, discusses...
04/06/2019
Oncology
Debates and Roundtables
12/21/2018
Jeff Sharman, MD, Anthony Mato, MD, MSCE, and Chaitra Ujjani, MD, discussed the findings of an interim analysis from the prospective informCLL real-world registry and how to optimize CLL treatment in real-world practice.
Jeff Sharman, MD, Anthony Mato, MD, MSCE, and Chaitra Ujjani, MD, discussed the findings of an interim analysis from the prospective informCLL real-world registry and how to optimize CLL treatment in real-world practice.
Jeff Sharman, MD, Anthony Mato,...
12/21/2018
Oncology